Table 2.
Somatic status and biomaterial assessed at various timepoints throughout the study.
| Analysis | Sample | Timepoint | ||
|---|---|---|---|---|
| Baseline | Week 8 | Week 12 | ||
| Somatic blood-sample screening |
Hemoglobin, white blood cell count, metamyelo.+myelo.+promyelocytes. C-reactive protein. | X | X | X |
| Na+, K+, Creatinine | X | |||
| ASAT, ALAT, GGT, LDH, BAP | X | |||
| Albumin, Coagulation factors II+VI+X, thrombocytes | X | |||
| B12, Folate | X | |||
| 25-OH-vitamin D | X | |||
| Blood sugar, HbA1c | X | |||
| Triglycerides, total-cholesterol, HDL, LDL | X | |||
| TSH, Ionized Calcium | X | |||
| Estradiol, testosterone, progesterone, FSH (females) | X | |||
| Somatic examination | Electro Cardiogram (ECG) Neurological status Somatic status |
X X X |
||
| Compliance to medicine control | S -escitalopram or S -duloxetine | X | ||
| Biobank | Inflammation and cytokines (hsCRP, TNF-α, IL-6, IL-18 and IL-10) | X | X | X |
| Biobank | Epigenetics (5-HTT, glucocortocoid-, FKBP5, COMT, MAO-A, estrogen-, oxytocin receptor and oxytocin gene-methylation) |
X | X | X |
| Biobank | Genotypes (rs41271330, 5-HTTLPR, COMT, BDNFval66met) |
X | ||
| Biobank | Gene transcription profiles (mRNA and microRNA, ABCB1, FZD7 and WNT2B) |
X | X | X |
| Oxidative stress | Urine (8-oxo-dG and 8-oxo-Guo) | X | X | |
| Biobank | Saliva (Cortisol awakening response) | X | X | |